PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 83
- Registration Number
- NCT00471276
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Everett, Washington, United States
A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Drug Product
Completed
- Conditions
- Siderosis
- Interventions
- Other: Observational Trial
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2011-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00471224
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Houston, Texas, United States
Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss
Not Applicable
Completed
- Conditions
- Obesity
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2008-09-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 350
- Registration Number
- NCT00471172
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.
Phase 2
Withdrawn
- Conditions
- Breast Neoplasms
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00471159
A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2010-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00468975
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Manchester, United Kingdom
Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease
Not Applicable
Completed
- Conditions
- Alzheimer DiseaseCaregivers
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00467766
- Locations
- ๐บ๐ธ
Aging and Dementia Research Center, Silberstein Institute, NYU School of Medicine, New York, New York, United States
๐ฆ๐บPrince of Wales Hospital, Randwick, New South Wales, Australia
๐ฌ๐งUniversity of Manchester, Division of Psychiatry, Manchester, United Kingdom
Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.
Withdrawn
- Conditions
- Abscess, Intra-AbdominalCholecystitisWound InfectionsPeritonitisAppendicitis
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2011-04-22
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00463762
A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers
Phase 1
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2008-11-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 73
- Registration Number
- NCT00463918
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Slough, Berkshire, United Kingdom
Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia
Phase 1
Completed
- Conditions
- SchizophreniaSchizo-affective Disorder
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00463372
- Locations
- ๐ฟ๐ฆ
Pfizer Investigational Site, George, South Africa
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
Phase 1
Completed
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 187
- Registration Number
- NCT00460603
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Vancouver, Washington, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath